Baylor College of Medicine

NanoPac Therapy for Mucinous Pancreatic Cyst (H-41791)

Description

Content

A Trial Evaluating Escalating Doses and the Safety of Intracystic Injection of NanoPac in Subjects With Mucinous Cystic Pancreatic Neoplasms

This study will evaluate the safety and tolerability of NanoPac when it is injected directly into mucinous pancreatic cysts. Three sites in the U.S. are participating. If you are over 18 and have a mucinous pancreatic cyst you may qualify for this study.

Participation in this clinical study will last for about six and a half months and during this time you will be asked to visit the study center up to eight times. You will have seven office visits and one procedure visit where NanoPac is injected into the cyst cavity after removal of the mucinous cyst fluid. Assessments will be performed at all study visits by the study doctor to monitor your health.

Benefits

  • Compensation provided for travel and parking expenses
  • Investigational medication provided at no charge
  • Study-related visits and assessments at no charge

IRB: H-41791

Status:

Active

Created:

Back to topback-to-top